In reports of industry-funded studies that compared the ocular hypotensive efficacy of topical prostaglandins, conclusions in the article abstracts differed from the results of the main outcome measure 62 percent of the time.
Thomas W. LeBlanc, MD, MA, MHS and Arif H. Kamal, MD, MBA, MHS
Clinical trials should assess patients’ distress and test interventions to address it, just as they assess adverse events and test novel therapeutic agents.
AMA J Ethics. 2017;19(5):460-466. doi:
10.1001/journalofethics.2017.19.5.stas1-1705.
The Moseley study found no significant difference between those in the arthroscopic lavage and debridement arm of the study and those in the sham surgery arm.
The harms of communicating autism risk can be avoided by helping families to understand risk and to distinguish between poor and good sources of scientific information, which should take families’ interests into account.
AMA J Ethics. 2015;17(4):323-327. doi:
10.1001/journalofethics.2015.17.4.nlit1-1504.
Hilary Daniel joins Ethics Talk to discuss her article, coauthored with Courtney Perlino and Dr Amy B. Cadwallader: “Which Drugs Should Be on the Essential Medicines List?”
Thomas W. LeBlanc, MD, MA and Amy P. Abernethy, MD, PhD
One strategy to promote adherence is the use of “care pathways,” effectively roadmaps that seek to standardize cancer treatment on the basis of some agreed-upon set of guidelines within a particular center or group of patients.
The high price of cancer drugs in the US relative to European countries with universal health care raises ethical issues of access, financial burden on patients, and unsustainability of the health care system.
AMA J Ethics. 2015;17(8):750-753. doi:
10.1001/journalofethics.2015.17.8.nlit1-1508.